The net profit of 40 billion vaccines in the first half of the year was reduced by at least 60 %, and the reorganized VSV new crown vaccine made no new progress.

Kangtai Bio is expected to fall at least 60 % of the net profit in the first half of this year.

On July 24, Shenzhen Kangtai Biological Products Co., Ltd. (Kangtai Biology, 300601) released the semi -annual performance preview this year, saying that the net profit attributable to shareholders of listed companies in the first half of the year was 100 million yuan to 130 million yuan, a decrease of 70.29% from the same period last year last year. To 61.37%; non -net profit of 65.902 million yuan to 95.922 million yuan, a decrease of 77.74%from the same period last year to 67.61%.

Kangtai Biological Semi -annual Report Trailer Data

Regarding the reason for the sharp decline in net profit, Kangtai Bio said that the main reason is the impairment of the assets related to the new crown and active vaccine and the cost of clinical expenditure phase III. Or affected by the above news, the stock price of Kangtai Bio fell sharply on July 25, with a maximum decline of more than 9%. As of the afternoon, it fell 6.41%to 35.75 yuan/share, with a market value of 4.06 billion yuan.

On the morning of July 25, Surging News contacted the Kangtai Biological Securities Department as an investor. The staff emphasized that the reason for the decline in net profit is based on the announcement.

In the latest performance trailer, Kangtai Bio has a large change in the new crown vaccination environment since the second quarter, the demand for the new crown vaccine has dropped rapidly, and the company's new crown vaccine sales have fallen rapidly; In the clinical stage, due to the influence of the Russian and Ukraine War, the blindness of the phase III clinical data in Ukraine was delayed, and subsequent sales were greatly uncertain.

In addition, Kangtai Bio has a new crown vaccine -related inventory commodity, raw and auxiliary materials, self -made semi -finished products, and the new crown vaccine development expenditure for the end of March 2022.4589.3 billion yuan; in addition, the new crowns that occurred in the second quarter The expenses of the R & D expenditure of the activated vaccine were 1402.2 million yuan; the total amount of the expenses of asset impairment preparation and confirmation of the cost of the research and development expenditure totaled the total profit of 5.54809.3 billion yuan. Considering the impact of the deduction and reducing net profit by 451.6 million yuan.

Kangtai Bio was founded in September 1992 and is headquartered in Shenzhen. It started with vaccine. It was listed on the GEM of the Shenzhen Stock Exchange on February 7, 2017, with a maximum market value of more than 100 billion yuan. According to the 2021 report, the main products of Kangtai Biological include reorganization of hepatitis B vaccine (brewing yeast), 13 -valent pneumococcal polysaccharide vaccine, type B influenzaobacillus combined vaccine, measles rubella combined with poisoning vaccine, and cytophyllless Bai Bai B. Bacteria of Bacteria of Bacteria combined with 23 -valent pneumococcal polysaccharide vaccine.

In contrast to the pre -decline of net profit in half a year, Kangtai Bio is expected to operate in the first half of the year, with a operating income of 18.27843.9 billion yuan, an increase of 73.72%year -on -year. In addition, the company's performance in the first quarter of this year greatly increased, with main revenue of 871 million yuan, an increase of 214.6%year -on -year; net profit of home mother was 274 million yuan, an increase of 987.71%year -on -year; and non -net profit of 248 million yuan, an increase of 2763.78%year -on -year.

The reason for the increase in net profit in the first half of the year and the increase in revenue, Kangtai Bio said that the main product of the four couplets of seedlings (Note: non -cell -free Bai Bai Bai B. Sales revenue of the sales revenue of infectious diseases caused by Bacillus, leukoplamis, tetanus sparbaccin and B. Bacterium B.) sales revenue increased by about 60.13%compared with the same period of the previous year. The sales revenue of hepatitis B vaccine increased by about 20.76%compared with the same period of the previous year. The company's newly listed product 13 -valent pneumococcal polysaccharide binding vaccine is gradually capacity.

Since the global new crown epidemic, Kangtai Bio has a new crown vaccine in three technical routes in different forms, which has promoted its stock price to rise. In early August 2020, the highest stock price exceeded 150 yuan/share.

Three new crown vaccines of Kangtai Biological Layout

The first is an active vaccine: On September 29, 2020, Kangtai Biological announced that its new crowned vaccine was approved by clinical trials. The vaccine was urgently used in China in May 2021 and has been approved as the same as the same. The source strengthens immune vaccination; the second is the adenovic vector vaccine: In August 2020, Kangtai Biological and Astraon signed an exclusive authorized cooperation framework agreement in the Chinese market to actively promote the Chadox1 glands cooperated with Astraikon and Oxford University through technical transfer. Virus carrier vaccines are developed, produced, supplied, and commercialized in the mainland market in China; the third is the reorganization of VSV virus vector vaccine. While disclosed the clinical trial approval in September 2020, Kangtai Bio mentioned that the vaccine was in the preclinical research stage.

Although in the middle of 2021, Kangtai Bio's activity vaccine has been launched in China, whether it is 2021 or this year's first quarter report and the latest semi -annual report, Kangtai Bio has not disclosed data on the issuance of the new crown vaccine or sales.

According to the 2021 report, the company's reorganized new coronary virus vaccine (Y25 gonad virus carrier) was urgently authorized by the Indonesian National Pharmaceutical and Food Regulatory Administration in October 2021 and achieved exports.On July 25, the reporter contacted the Kangtai Biological Securities Affairs Department as an investor. The staff said on the phone that the reorganization of the new coronary virus vaccine (Y25 adenovirus carrier) was the new crown vaccine in cooperation with Astraikon.As for the reorganized VSV virus vector vaccine, there is no new progress. At present, the company's main promotion is the two new crown vaccines of the activation and the adenovirus vector.According to the latest performance preview, Kangtai's performance is affected by the development of the new crown vaccine, and whether the company's subsequent investment in the new crown vaccine will be reduced, the above -mentioned staff said that the specifics are unclear.

- END -